ClinicalTrials.gg
CompletedNCT02967224Reach-ControlUpdated Apr 25, 2022

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin

A Phase 4 interventional study of insulin glargine (U300) and insulin glargine (U100) in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 128 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
705
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
26th of 175
705 · median 253
Started
2015
with 13 others
Phase 4
103 of 176
2 open now
Registered
138th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 26th largest by enrollment of the 175 interventional ones that give a count, is one of 14 that started in 2015, is one of 103 in phase 4, and was the 138th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate noninferiority of Toujeo versus "standard of care" basal insulin therapy measured as glycosylated hemoglobin (HbA1c) change

Secondary Objectives:

  • To demonstrate superiority of Toujeo versus "standard of care" basal insulin if noninferiority is met, measured as HbA1c change.
  • To compare Toujeo to other "standard of care" basal insulin in terms of patient persistence with assigned basal insulin therapy with or without intensification.
  • Risk of hypoglycemia including the incidence of documented symptomatic or severe hypoglycemic events [as defined by the American Diabetes Association (ADA] Workgroup on Hypoglycemia).
  • Change in fasting plasma glucose (FPG).
  • Change in body weight.
  • Differences in patient reported outcomes measured by Diabetes Treatment Satisfaction Questionnaire Status and Change Versions (DTSQs and DTSQc).
  • Change in hypoglycemic control subscale (HCS)
  • Healthcare resource utilization including hospitalizations and emergency department or other health care provider visits and healthcare costs.
Read the detailed description

The total study duration will be up to 55 weeks, consisting of a 1-week screening period at the site, a 26-week treatment period, and a 26-week extension period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with type 2 diabetes insufficiently controlled ( >7%) with current (≥6 months) standard of care with oral agents (metformin, sulfonylurea, thiazolidinediones, DPP-4 inhibitor, SGLT-2 inhibitor, glinides, α glucosidase inhibitors) and with or without GLP-1 receptor agonist, and eligible to basal insulin treatment, per investigator's judgment.

Exclusion criteria

Exclusion criteria:

  • ≤7%, no upper bound.
  • Age \<18 years.
  • Type 1 diabetes mellitus.
  • Any abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening, or any major systemic disease resulting in short that in the opinion of the Investigator would restrict or limit the patient's successful participation for the duration of the study.
  • Use of any product containing insulin since the time of diagnosis with T2DM other than temporary use during a pregnancy or hospitalization.
  • Use of any product containing insulin occurring within 3 months prior to the time of screening.
  • Use of oral hypoglycemic agents other than those noted in the inclusion criteria, GLP 1 receptor agonists not approved for use with insulin, or any agent (drug, biologic, device) within 3 months prior to the time of screening.
  • All to commercially available insulin therapy or warnings/precautions of use as displayed in the respective National Product labeling for these products.
  • to insulin glargine or Toujeo .
  • Patient is the Investigator or any Sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
  • Pregnancy or lactation.
  • Women of with no effective method.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
705 participants (actual)

Study arms

  • Experimental
    Toujeo

    Toujeo will be administered once daily in addition to noninsulin antidiabetic agents

    Drug: insulin glargine (U300)

  • Active comparator
    "Standard of care" commercially available basal insulin

    Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir or Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to noninsulin antidiabetic agents

    Drug: insulin glargine (U100) · Drug: NPH insulin · Drug: insulin detemir · Drug: insulin degludec

Interventions

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: HOE901; Toujeo

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: HOE901; Lantus

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Humulin NPH

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Levemir

  • Pharmaceutical form: solution Route of administration: subcutaneous

    Also known as: Tresiba

06

What researchers measure

Primary outcomes

  1. Change in HbA1c (percentage %)

    Time frame: Baseline to 6 Months

Secondary outcomes

  1. Proportion of patients who remain on assigned basal insulin therapy before intensification (persistent with assigned therapy)

    Time frame: At Month 6 and Month 12

  2. Proportion of patients who remain on assigned basal insulin therapy whether intensification occurred or not

    Time frame: At Month 6 and Month 12

  3. Proportion of patients who achieve target HbA1c (<6.5%, <7%, <7.5%,<8.0%)

    Time frame: At Month 6 and Month 12

  4. Proportion of patients with HbA1c target (thresholds listed above; attainment of metabolic benefit) without documented (blood glucose (BG) ≤70 mg/dL [3.9 mmol/L]) symptomatic or severe hypoglycemia

    Time frame: At Month 6 and Month 12

  5. Proportion of patients with HbA1c target (thresholds listed above; attainment of metabolic benefit) without documented (BG <54 mg/dL [3.0 mmol/L]) symptomatic or severe hypoglycemia

    Time frame: At Month 6 and Month 12

  6. Change in HbA1c (percentage %)

    Time frame: Baseline to Month 12

  7. Percentage of patients whose HbA1c decreased at least 1%

    Time frame: At Month 6 and Month 12

  8. Percentage of patients whose HbA1c decreased at least 1%

    Time frame: At Month 6 and maintained at Month 12

  9. Percentage of patients requiring intensification

    Time frame: At Month 6 and Month 12

  10. Time to intensification

    Time frame: At Month 6 and Month 12

  11. Change in fasting plasma glucose

    Time frame: Baseline to Month 6 and Month 12

07

Study locations

128 sites
  • Investigational Site Number 076-001
    Curitiba, 80810-140, Brazil
  • Investigational Site Number 076005
    Fortaleza, 60115-282, Brazil
  • Investigational Site Number 076004
    Fortaleza, Brazil
  • Investigational Site Number 076009
    Rio de Janeiro, 202110340, Brazil
  • Investigational Site Number 076008
    Sao Paulo, 01244-030, Brazil
  • Investigational Site Number 076011
    São José dos Campos, 12243-280, Brazil
  • Investigational Site Number 076007
    São paulo, 01223-001, Brazil
  • Investigational Site Number 076003
    São Paulo, 04024-002, Brazil
  • Investigational Site Number 076010
    Taguatinga, 72155000, Brazil
  • Investigational Site Number 250060
    Alencon Cedex, 61014, France
  • Investigational Site Number 250023
    Amiens Cedex 1, 80054, France
  • Investigational Site Number 250057
    Bar le Duc, France
  • Investigational Site Number 250050
    BETHUNE Cedex, 62408, France
  • Investigational Site Number 250008
    BOIS GUILLAUME Cedex, 76233, France
  • Investigational Site Number 250024
    Bordeaux, 33000, France
  • Investigational Site Number 250028
    Brest, 29000, France
  • Investigational Site Number 250014
    Caen, 14000, France
  • Investigational Site Number 250003
    CAHORS Cedex 9, 46005, France
  • Investigational Site Number 250064
    CHALONS EN CHAMPAGNE Cedex, 51005, France
  • Investigational Site Number 250026
    Cholet, 49300, France
  • Investigational Site Number 250025
    Corbeil Essonnes, 91100, France
  • Investigational Site Number 250011
    Eaubonne, France
  • Investigational Site Number 250013
    La Roche Sur Yon, 85025, France
  • Investigational Site Number 250058
    La Rochelle Cedex 1, 17019, France
  • Investigational Site Number 250027
    La Seyne sur Mer, France
  • Investigational Site Number 250034
    Lamagistere, 82360, France
  • Investigational Site Number 250017
    Le Puy En Velay Cedex, 43012, France
  • Investigational Site Number 250012
    Marseille, 13008, France
  • Investigational Site Number 250054
    Maubeuge, 59600, France
  • Investigational Site Number 250045
    Montpellier, 34059, France
  • Investigational Site Number 250020
    Montpellier, 34295, France
  • Investigational Site Number 250016
    Montpellier, France
  • Investigational Site Number 250035
    Mulhouse, France
  • Investigational Site Number 250004
    NARBONNE Cedex, 11018, France
  • Investigational Site Number 250046
    Nevers, 58000, France
  • Investigational Site Number 250041
    Nimes, 30029, France
  • Investigational Site Number 250044
    Orleans, 45100, France
  • Investigational Site Number 250063
    Paris, 75012, France
  • Investigational Site Number 250053
    Paris, 75014, France
  • Investigational Site Number 250005
    Paris, 75018, France
  • Investigational Site Number 250032
    Paris, 75020, France
  • Investigational Site Number 250021
    Pierre-Bénite, 69310, France
  • Investigational Site Number 250030
    Pierre-Bénite, 69310, France
  • Investigational Site Number 250052
    POITIERS Cedex, 86021, France
  • Investigational Site Number 250051
    PRINGY Cedex, 74374, France
  • Investigational Site Number 250039
    Reims Cedex, 51092, France
  • Investigational Site Number 250022
    Roubaix, 59100, France
  • Investigational Site Number 250033
    Saint-Mandé, 94160, France
  • Investigational Site Number 250055
    Sete, 34200, France
  • Investigational Site Number 250031
    Strasbourg Cedex 2, 67098, France
  • Investigational Site Number 250056
    Strasbourg, 67000, France
  • Investigational Site Number 250001
    Strasbourg, 67091, France
  • Investigational Site Number 250043
    Tarbes, 65013, France
  • Investigational Site Number 250002
    Toulouse Cedex 3, 31076, France
  • Investigational Site Number 250029
    Vandoeuvre Les Nancy Cedex, 54511, France
  • Investigational Site Number 250009
    Venissieux, 69200, France
  • Investigational Site Number 250007
    VICHY Cedex, 03201, France
  • Investigational Site Number 250006
    Vichy, 03200, France
  • Investigational Site Number 250059
    Villeneuve sur Lot, 47300, France
  • Investigational Site Number 276013
    Bornheim, 53332, Germany
  • Investigational Site Number 276002
    Dresden, 01279, Germany
  • Investigational Site Number 276001
    Dresden, 01307, Germany
  • Investigational Site Number 276016
    Hamburg, 22607, Germany
  • Investigational Site Number 276014
    Hohenmölsen, 06679, Germany
  • Investigational Site Number 276017
    Münster, 48153, Germany
  • Investigational Site Number 276012
    Neumünster, 24534, Germany
  • Investigational Site Number 276009
    Neuwied, 56564, Germany
  • Investigational Site Number 276008
    Oldenburg, 26133, Germany
  • Investigational Site Number 276006
    Pirna, 01796, Germany
  • Investigational Site Number 276010
    Rehlingen-Siersburg, 66780, Germany
  • Investigational Site Number 276005
    Riesa, 01587, Germany
  • Investigational Site Number 276011
    Schweinfurt, 97421, Germany
  • Investigational Site Number 276007
    Sulzbach-Rosenberg, 92237, Germany
  • Investigational Site Number 372003
    Dublin 4, Ireland
  • Investigational Site Number 327002
    Dublin 7, Ireland
  • Investigational Site Number 642001
    Bucuresti, 010825, Romania
  • Investigational Site Number 642002
    Bucuresti, 022441, Romania
  • Investigational Site Number 642007
    Bucuresti, Romania
  • Investigational Site Number 642004
    Cluj-Napoca, 400006, Romania
  • Investigational Site Number 642005
    Galati, 800291, Romania
  • Investigational Site Number 642009
    Iasi, Romania
  • Investigational Site Number 642006
    Oradea, 410169, Romania
  • Investigational Site Number 642008
    Targoviste, 130083, Romania
  • Investigational Site Number 724013
    Almansa, 02640, Spain
  • Investigational Site Number 724024
    Badalona, 08915, Spain
  • Investigational Site Number 724016
    Barakaldo, 48903, Spain
  • Investigational Site Number 724005
    Barcelona, 08025, Spain
  • Investigational Site Number 724019
    Barcelona, 08035, Spain
  • Investigational Site Number 724017
    Barcelona, Spain
  • Investigational Site Number 724008
    Burgos, Spain
  • Investigational Site Number 724018
    Donostia, 20014, Spain
  • Investigational Site Number 724026
    Ferrol, 15405, Spain
  • Investigational Site Number 724021
    Gerona, 17007, Spain
  • Investigational Site Number 724027
    Huelva, 21005, Spain
  • Investigational Site Number 724014
    La Coruña, 15006, Spain
  • Investigational Site Number 724001
    LLeida, Spain
  • Investigational Site Number 724025
    Madrid, 28040, Spain
  • Investigational Site Number 724028
    Madrid, 28041, Spain
  • Investigational Site Number 724006
    Majadahonda, 28222, Spain
  • Investigational Site Number 724030
    Málaga, 29004, Spain

Showing the first 100 of 128 sites across 7 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4. PubMed 33166419 ↗
  • Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyen-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Curr Med Res Opin. 2020 Apr;36(4):571-581. doi: 10.1080/03007995.2019.1708287. Epub 2020 Jan 19. PubMed 31865758 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Oct 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2016
First posted
Nov 18, 2016
Start
Nov 5, 2015
Primary completionActual
Oct 16, 2017
CompletionActual
Oct 16, 2017
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02967224
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 18, 2016
Start date
Nov 5, 2015
Primary completion
Oct 16, 2017
Completion
Oct 16, 2017
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion